drugset / Trial / NCT06986382

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

NCT06986382 ↗

Phase 1/2 Not yet recruiting 14 enrolled Stanford University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is investigating whether alpha beta T-cell depleted hematopoietic stem cell transplant (HSCT) can be an immune system replacement for Crohn disease patients and whether this is safe and effective for patients with early onset, medically refractory Crohn disease.

Timeline

Start
2025-07
Primary completion
2037-07
Completion
2040-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background ATG Unknown — —
Background Clofarabine Other / unclassified — —
Background Melphalan Small molecule — —
Background Methylprenisolone Unknown — —
Background Palifermin Protein / enzyme biologic — —
Background Prednisone Other / unclassified — —
Background Rituximab Monoclonal antibody — —

Indications